A biotherapeutic player that insiders are active in here is Pozen (POZN), which focuses on migraine treatment through the use of triptans and different delivery mechanisms. Insiders are buying this stock into notable strength, since shares are up 13% so far in 2013.
Pozen has a market cap of $172 million and an enterprise value of $87 million. This stock trades at a reasonable valuation, with a forward price-to-earnings of 25.73. Its estimated growth rate for this year is 69%, and for next year it's pegged at 184.6%. This is a cash-rich company, since the total cash position on its balance sheet is $80.19 million and its total debt is zero.>>4 Health Care Stocks Under $10 Close to Breakouts A beneficial owner just bought 90,000 shares, or about $472,000 worth of stock, at $5.25 per share. From a technical perspective, POZN is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last three months, with shares moving higher from its low of $4.26 to its intraday of $5.75 a share. During that move, shares of POZN have been mostly making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of POZN within range of triggering a near-term breakout trade. If you're in the bull camp on POZN, then look for long-biased trades as long as this stock is trending above its 50-day at $5.19 and then once it breaks out above some near-term overhead resistance levels at $5.64 to $6.11 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 205,580 shares. If that breakout triggers soon, then POZN will set up to re-test or possibly take out its 52-week high at $6.95 a share. Any high-volume move above that level will then put its next major resistance levels at $7.55 to $8.12 into range for shares of POZN.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV